In Vitro Antitumor Activity of Newly Synthesized Pyridazin-3(2H)-One Derivatives via Apoptosis Induction


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Только для подписчиков

Аннотация

Systemic toxicity associated with drug resistance continues to be the major obstacle to curative therapy of cancer. Tumor cell resistance to chemotherapeutic drugs often results in coordinate resistance to other structurally and functionally unrelated drugs and the subsequent development of cross resistance phenotype. Therefore, it seems necessary to identify new molecules as anticancer agents. In this process, we synthesized a series of new pyridazin-3(2H)-one derivatives and evaluated their antitumor potential. These cyclic molecules were synthesized and designed as a combination of benzofuran with pyridazinones. All final compounds have been characterized by spectral and elemental analyses to confirm successful synthesis reactions. To evaluate their anticancer activity, all derivatives were assessed against the human breast adenocarcinoma cell line (MCF-7) and the murine mastocytoma cell line (P815) using the methyl tetrazolium Test (MTT assay). The cytotoxic activity was found to be dose-dependent and the IC50 values of the synthesized compounds ranged from 14.5 to 40 μM against MCF-7 and from 35 to 82.5 μM against P815. At the same time, no cytotoxic activity was observed against normal cells. In order to investigate the molecular mechanism of the most cytotoxic product (6f), apoptosis induction was measured against MCF-7 cells. Using the annexin-V FITC staining technique, we showed that the cytotoxic effect of this product is associated with apoptosis induction.

Об авторах

Najat Bouchmaa

Laboratory of Medicinal Chemistry, Faculty of Medicine and Pharmacy, Mohammed V University; Laboratory of Biological Engineering, Natural Substances, Team of Cellular and Molecular Immuno-Pharmacology, Immunobiology of Cancer Cells, Faculty of Sciences and Technologies, Sultan Moulay Slimane University

Email: ab.zyad2@gmail.com
Марокко, Rabat; Beni-Mellal

Mounir Tilaoui

Laboratory of Biological Engineering, Natural Substances, Team of Cellular and Molecular Immuno-Pharmacology, Immunobiology of Cancer Cells, Faculty of Sciences and Technologies, Sultan Moulay Slimane University

Email: ab.zyad2@gmail.com
Марокко, Beni-Mellal

Youness Boukharsa

Laboratory of Medicinal Chemistry, Faculty of Medicine and Pharmacy, Mohammed V University

Email: ab.zyad2@gmail.com
Марокко, Rabat

Abdessalam Jaâfari

Laboratory of Biological Engineering, Natural Substances, Team of Cellular and Molecular Immuno-Pharmacology, Immunobiology of Cancer Cells, Faculty of Sciences and Technologies, Sultan Moulay Slimane University

Email: ab.zyad2@gmail.com
Марокко, Beni-Mellal

Hassan Mouse

Laboratory of Biological Engineering, Natural Substances, Team of Cellular and Molecular Immuno-Pharmacology, Immunobiology of Cancer Cells, Faculty of Sciences and Technologies, Sultan Moulay Slimane University

Email: ab.zyad2@gmail.com
Марокко, Beni-Mellal

My. Ali Oukerrou

Laboratory of Biological Engineering, Natural Substances, Team of Cellular and Molecular Immuno-Pharmacology, Immunobiology of Cancer Cells, Faculty of Sciences and Technologies, Sultan Moulay Slimane University

Email: ab.zyad2@gmail.com
Марокко, Beni-Mellal

Jamal Taoufik

Laboratory of Medicinal Chemistry, Faculty of Medicine and Pharmacy, Mohammed V University

Email: ab.zyad2@gmail.com
Марокко, Rabat

M’hammed Ansar

Laboratory of Medicinal Chemistry, Faculty of Medicine and Pharmacy, Mohammed V University

Email: ab.zyad2@gmail.com
Марокко, Rabat

Abdelmajid Zyad

Laboratory of Biological Engineering, Natural Substances, Team of Cellular and Molecular Immuno-Pharmacology, Immunobiology of Cancer Cells, Faculty of Sciences and Technologies, Sultan Moulay Slimane University

Автор, ответственный за переписку.
Email: ab.zyad2@gmail.com
Марокко, Beni-Mellal


© Springer Science+Business Media, LLC, part of Springer Nature, 2018

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах